Related Experiment Video
Updated: Jul 9, 2026
07:10
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all
Julia L Hurwitz1, Timothy D Lockey, Bart Jones
1Department of Immunology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
AIDS (London, England)
|December 20, 2007
Abstract:
To combat HIV-1 diversity, we are developing a multienvelope vaccine (comprising DNA, vaccinia virus and protein vectors). Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant.
